- Home
- BLW vs BWAY Comparison
BLW vs BWAY Comparison
Compare BLW & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLW | BWAY |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.2M | 451.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BLW | BWAY |
|---|---|---|
| Price | $13.77 | $24.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 85.9K | ★ 125.1K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | ★ 1.81 | 0.13 |
| Revenue | N/A | ★ $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ $7.73 | $79.08 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $12.35 | $7.84 |
| 52 Week High | $14.26 | $25.64 |
Technical Indicators
Market Signals| Indicator | BLW | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 64.20 |
| Support Level | $13.72 | $22.90 |
| Resistance Level | $13.81 | $24.78 |
| Average True Range (ATR) | 0.07 | 1.17 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 41.97 | 73.66 |
Price Performance
Historical ComparisonAbout BLW Blackrock Limited Duration Income Trust
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.